Skip to main content
. 2022 Mar;11(3):569–579. doi: 10.21037/tcr-22-344

Figure 5.

Figure 5

Summary of CRS incidence during CAR-T therapy for RRMM (subgrouped by motif) (10-14,16-19). CI, confidence interval; CRS, cytokine release syndrome; CAR, chimeric antigen receptor; RRMM, relapsed or refractory multiple myeloma.